ACR 2018 Congress Highlights Brochure

Enhancing knowledge of the clinical
importance of cytokine signalling
The Cytokine Signalling Forum
www.cytokinesignalling.com
ACR 2018
Conference Highlights
Find us at Booth C35
Developed under
the auspices of the
University of Glasgow
Register for all this FREE content at
www.cytokinesignalling.com

Steering Committee
Professor Iain B. McInnes
University of Glasgow,
UK
CHAIR
Professor Johannes W.J. Bijlsma
University Medical Centre,
Utrecht, The Netherlands
Professor Maurizio Cutolo
University of Genova,
Italy
Professor Cem Gabay
University Hospitals of Geneva,
Switzerland
Professor Juan J. Gómez-Reino
University Hospital,
Santiago de Compostela, Spain
Professor Ahmet Gül
Istanbul University,
Turkey
Professor Pierre Miossec
Hôpital Edouard Herriot, Lyon,
France
Professor Peter Nash
University of Queensland,
Brisbane, Australia
Professor John J. O’Shea
NIAMS, Maryland,
USA
Professor Georg Schett
University of Erlangen-Nuremberg,
Erlangen, Germany
Professor Tsutomu Takeuchi
Keio University, Tokyo, Japan
DEVELOPMENT PARTNERS
Professor Kevin Winthrop
Oregon Health and Science
University, USA

Chairman’s Welcome
Dear CSF Member,
Following the continued success of the Cytokine Signalling Forum, it is my pleasure to welcome you to our selection of
the ACR 2018 abstracts. The selection includes my ‘Chairman’s Picks,’ abstracts that I feel have the most significant
impact on cytokine signalling science.
This year it is exciting to see more data supporting the use of JAK inhibitors in rheumatoid arthritis, with new Phase 3
data released for two unapproved JAK inhibitors. Two Phase 3 peficitinib abstracts are presented with results from two
different patient populations: DMARD inadequate responders [#887] and methotrexate inadequate responders [#888].
In addition, upadacitinib Phase 3 data continues to be presented following the abstracts at EULAR earlier this year. Smolen
presents data on upadacitinib monotherapy in methotrexate inadequate responders [#889], followed by an investigation by
van Vollenhoven of upadacitinib monotherapy in methotrexate-naïve patients [#891]. The upadacitinib Phase 3 data also
includes an upadacitinib comparison study in methotrexate inadequate responders presented by Fleischmann [#890].
Updates on the long-term safety profile of baricitinib are presented in a 6-year integrated safety analysis presented by
Genovese [#962], with a focus on cardiovascular safety discussed by Weinblatt [#2815].
Similar data is presented on tofacitinib within a longer-term safety analysis study containing data up to 9.5 years [#963].
Cardiovascular disease risk associated with tofacitinib was evaluated in comparison to csDMARD in patients with RA
[#2817], and herpes zoster risk is analysed in an abstract by Curtis using data over a 5-year period [#885]. Tofacitinib
clinical effectiveness is also evaluated in an observational cohort by Cohen [#580].
We also have long-term safety data on filgotinib in patients with RA, using data up to 132 weeks [#2551]. Outside
RA, filgotinib is showing positive Phase 2 data in psoriatic arthritis and in csDMARD inadequate responders
presented by Mease [#1821].
In this booklet, you will find our selection of the abstract highlights from ACR 2018 with my ‘Chairman’s Picks’ highlighted.
As always, thank you for your continued support of the Cytokine Signalling Forum and we hope you enjoy your time at
ACR in Chicago this year!
Don’t forget to visit us at the Cytokine Signalling Forum stand at ACR.
Kind regards,
Professor Iain McInnes

Key Presentations
Sunday, 21 October 2018
ACR POSTER SESSION A: 9 :00 – 11:00 AM
Rheumatoid Arthritis – Animal Models Poster
37 Discovery of DWP213388, a Potent ITK and
BTK Dual Target Inhibitor with Excellent Efficacy,
as a Treatment for Autoimmune Diseases
Epidemiology and Public Health Poster I:
Rheumatoid Arthritis
224 Risk of Venous Thrombotic Events in
Rheumatoid Arthritis Patients Initiating
Tofacitinib or Adalimumab
Rheumatoid Arthritis – Diagnosis,
Manifestations, and Outcomes Poster I:
Comorbidities
525 Low Interstitial Lung Disease Event Rate in
Patients with Rheumatoid Arthritis: Pooled
Post Hoc Analysis of Data from the Tofacitinib
Clinical Development Program
Rheumatoid Arthritis – Treatment Poster I:
Strategy and Epidemiology
546 Baricitinib: Early vs. Delayed Start in Patients
with Rheumatoid Arthritis
557 The Impact of Comedication with Conventional
Synthetic DMARDs on Drug Retention and
Clinical Effectiveness of Tofacitinib, Anti–Tumor
Necrosis Factor Therapy and Biologics with
an Alternative Mode of Action in Patients with
Rheumatoid Arthritis. A Cohort Study
574 Longitudinal Efficacy Analysis of Patients with
Active Rheumatoid Arthritis and Inadequate
Response to Conventional Synthetic DMARDs:
Response Following Rescue from Baricitinib 2
mg to 4 mg Once-Daily
580 Clinical Effectiveness of Tofacitinib 11 mg
Once Daily (QD) versus Tofacitinib 5 mg Twice
Daily (BID) in the Corrona US RA Registry
581 Comparative Analysis of Outcomes among
Patients with Rheumatoid Arthritis Initiating
Tofacitinib in Combination with Oral MTX who
Discontinue, Interrupt, or Persist with MTX
582 Baseline Power Doppler and Multi-Biomarker
Disease Activity Score Predict 12-Week
Disease Activity Response to Tofacitinib
586 Effectiveness, Tolerability, and Safety
of Tofacitinib in Rheumatoid Arthritis: A
Retrospective Analysis of Real-World DATA
from the St. Gallen and Aarau RA-Cohort
596 Combination of Intra-articular Steroid Injection
and Tofacitinib More Effective than Tofacitinib in
Rapid Radiographic Progression Patients with
Rheumatoid Arthritis
599 Comparative Effectiveness in Pain and
HAQ-DI Improvement for Baricitinib versus
Adalimumab, Tocilizumab, and Tofacitinib
Monotherapies in csDMARD-naïve
Rheumatoid Arthritis Patients: A Matchingadjusted
Indirect Comparison (MAIC)
607 Clinical and Functional Response to Tofacitinib
and Adalimumab in Patients with Rheumatoid
Arthritis: Probability Plot Analysis of Results
from the ORAL Strategy Trial
629 Real-world Use of Tofacitinib Compared with
Tumor Necrosis Factor Inhibitors in a Cohort of
211 Patients with Rheumatoid Arthritis: Data
from a Drug-based Registry Study in Taiwan
Chairman’s picks

Spondyloarthritis including Psoriatic
Arthritis – Clinical Poster I: Imaging, Clinical
Studies, and Treatment
685 Changes in Key Laboratory Values with
Tofacitinib 5 mg BID Treatment in Patients with
Psoriatic Arthritis and Rheumatoid Arthritis
ACR CONCURRENT ABSTRACT SESSION:
2:30 – 4:00PM
3S086 ACR Abstract: RA–DX, Manifestations,
& Outcomes I: Other Co-Morbidities
885 Herpes Zoster in Tofacitinib Users with and without
Concomitant Methotrexate and Glucocorticoids
3S087 ACR Abstract: RA–Treatments I: JAK
Inhibitors
886 Efficacy and Safety of Switching from
Adalimumab to Baricitinib: Long-term Data
from Phase 3 Extension Study in Patients with
Rheumatoid Arthritis
887 Efficacy and Safety of the Novel Oral Janus
Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in
a Phase 3, Double-blind, Placebo-controlled,
Randomized Study of Patients with RA who had
an Inadequate Response to DMARDs
888 Efficacy and Safety of the Novel Oral Janus
Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in
a Phase 3, Double-blind, Placebo-controlled,
Randomized Study of Patients with RA who had
an Inadequate Response to Methotrexate
889 Upadacitinib As Monotherapy: A Phase 3
Randomized Controlled Double-blind Study in
Patients with Active Rheumatoid Arthritis and
Inadequate Response to Methotrexate
890 A Phase 3, Randomized, Double-blind
Study Comparing Upadacitinib to Placebo
and to Adalimumab, in Patients with Active
Rheumatoid Arthritis with Inadequate
Response to Methotrexate
891 A Phase 3, Randomized, Controlled Trial
Comparing Upadacitinib Monotherapy to MTX
Monotherapy, in MTX-naïve Patients with Active
Rheumatoid Arthritis
ACR CONCURRENT ABSTRACT SESSION:
4:30 – 6:00PM
3S107 ACR Abstract: RA–Etiology &
Pathogenesis I
930 Joint Location-specific IL-6 and JAK-STAT
Signaling in Rheumatoid Arthritis (RA) Fibroblastlike
Synoviocytes (FLS)
3S108 ACR Abstract: RA–Treatments II:
Safety
962 Safety Profile of Baricitinib for the Treatment of
Rheumatoid Arthritis up to 6 Years: An Updated
Integrated Safety Analysis
963 Long-term Safety of Tofacitinib up to 9.5 Years:
A Comprehensive Integrated Analysis of the RA
Clinical Development Program
3S110 ACR Abstract: SLE–Clinical I: Clinical
Trials
970 Baricitinib in Patients with Systemic Lupus
Erythematosus: Results from a Phase 2, Randomized,
Double-blind, Placebo-controlled Study
Chairman’s picks

Monday, 22 October 2018
ACR POSTER SESSION B: 9 :00 – 11:00 AM
Cytokines and Cell Trafficking Poster
983 A MAPK Activated Kinase 2 Inhibitor Attenuates
Inflammatory and Destructive Arthritis in
Human Ex Vivo Models
Innate Immunity Poster
1018 Tofacitinib Impairs Monocyte-derived Dendritic
Cell Differentiation in Rheumatoid Arthritis and
Psoriatic Arthritis
Measures and Measurement of Healthcare
Quality Poster II
1264 Modeling the Costs and Outcomes Associated
with Treatment Sequences, with and without
Tofacitinib, for Moderately to Severely Active
Psoriatic Arthritis in the US
Patient Outcomes, Preferences, and Attitudes
Poster I: Patient-reported Outcomes
1401 Is There a Specific Effect of JAK-inhibitors on
Pain and Fatigue in Rheumatoid Arthritis?
Rheumatoid Arthritis – Diagnosis,
Manifestations, and Outcomes Poster II:
Diagnosis and Prognosis
1495 Baseline Characteristics of Methotrexate
Inadequate Responder Patients with RA
who achieved Low Disease Activity with
Tofacitinib Monotherapy
Rheumatoid Arthritis – Treatments Poster II:
PROs, Safety and Comorbidity
1515 Malignancy in Japanese Patients with Rheumatoid
Arthritis Treated with Tofacitinib: Interim Analysis
of All-case Post-marketing Surveillance
1516 Infection Events in Japanese Patients with
Rheumatoid Arthritis Treated with Tofacitinib:
Interim All-case Post-marketing Surveillance
1518 Baricitinib and Tofacitinib in Real Life – Does
Obesity Impact Response to Janus Kinase
Inhibitor Therapy in Rheumatoid Arthritis?
1519 Patient Characteristics Associated with
Discontinuation of Tofacitinib for the Treatment
of Rheumatoid Arthritis in Open-label, Long-term
Extension Studies up to 9.5 Years
1525 Effect of JAK-inhibitor versus bDMARDs on
Quality of Life in Rheumatoid Arthritis: A Meta
Analysis of Randomized Controlled Trials
1527 Tofacitinib Improves Left Ventricular Mass and
Cardiac Output in Rheumatoid Arthritis Patients
with Chronic Heart Failure
1530 CRP Changes during Bacterial Infections in
Baricitinib-treated Patients with RA
1531 Tofacitinib Show Similar Retention When Used
with and without Methotrexate. Analysis from the
Rhumadata® Clinical Database and Registry
1536 Mean Platelet Volume Changes with Baricitinib
Indicate Reduced New Platelet Production in
Baricitinib-treated Rheumatoid Arthritis Patients
1537 Frequency and Duration of Early Non-serious
Adverse Events in Rheumatoid Arthritis Patients
Treated with Tofacitinib 5 mg Twice Daily as
Monotherapy and Combination Therapy
1542 Real-world Data from a Post-approval
Safety Surveillance Study of Tofacitinib vs
Biologic DMARDs and Conventional Synthetic
DMARDs: Five-year Results from a US-based
Rheumatoid Arthritis Registry

1544 Tofacitinib Safety and Efficacy in the Treatment
of Rheumatoid Arthritis in a Central/Eastern
European Subpopulation
1547 Impact of Obesity on Drug Survival of Tofacitinib
in Patients with Rheumatoid Arthritis: Analysis
from the Turkbio Registry
1554 Cigarette Smoking Does Not Affect Treatment
Response to Tofacitinib in Rheumatoid Arthritis
ACR PLENARY SESSION: 11:00 – 12:30 PM
4M042 ACR Abstract: Plenary Session II
1821 Filgotinib, an Oral, Selective Janus Kinase
1 Inhibitor, Is Effective in Psoriatic Arthritis
Patients with an Inadequate Response to
Conventional Disease-modifying Anti-rheumatic
Drugs: Results from a Randomized, Placebocontrolled,
Phase 2 Study
ACR CONCURRENT ABSTRACT SESSION:
4:30 – 6:00AM
4M108 ACR Abstract: SLE–Etiology &
Pathogenesis I
1894 Baricitinib-associated Changes in Type l
Interferon Gene Signature during a 24-Week
Phase-2 Clinical SLE Trial
Tuesday, 23 October 2018
ACR POSTER SESSION C: 9 :00 – 11:00 AM
Rheumatoid Arthritis – Diagnosis,
Manifestations, and Outcomes Poster III:
Complications of Therapy, Outcomes,
and Measures
2447 Liver Enzyme Abnormalities after Tofacitinib
Treatment in Patients with Hepatic Steatosis from
the Rheumatoid Arthritis, Psoriatic Arthritis, and
Psoriasis Clinical Programs
2454 Virus Reactivation Rate in Rheumatoid Arthritis
Using Tofacitinib
Rheumatoid Arthritis – Etiology and
Pathogenesis Poster III
2035 Effect of Baricitinib on Joint-related Biomarkers
in Patients with Moderate-to-severe
Rheumatoid Arthritis
Rheumatoid Arthritis – Treatments Poster
III: Biosimilars and New Compounds
2517 The JAK1-selective Inhibitor Filgotinib Reverses
the Disease-associated Transcriptional Profile
Found in the Blood of Patients with Active
Rheumatoid Arthritis
2518 GS-9876, a Novel, Highly Selective, SYK Inhibitor
in Patients with Active Rheumatoid Arthritis:
Safety, Tolerability and Efficacy Results of a
Phase 2 Study
2523 Rapid Response with Upadacitinib Treatment
in Patients with Rheumatoid Arthritis and an
Inadequate Response to csDMARDs or bDMARDs
2524 Effect of Upadacitinib on Pain and Morning
Stiffness in Patients with Rheumatoid Arthritis
and Inadequate Response to Conventional
Synthetic or Biologic Disease-modifying
Anti-rheumatic Drugs
2531 Assessment of Pain Relief with Baricitinib by
Treatment History in Patients with Refractory
Rheumatoid Arthritis
Chairman’s picks

2541 Impact of 12-Weeks of Upadacitinib Treatment
on Individual and Composite Disease Measures
in Patients with Rheumatoid Arthritis and
Inadequate Response to Conventional Synthetic
or Biologic DMARDs
2542 Integrated Exposure-response Analyses for
Upadacitinib Efficacy and Effects on Laboratory
Parameters in Rheumatoid Arthritis – Analyses of
Phase 2b Studies
2546 The Association between Patient Reported
Outcomes and Clinical Measures Among
Rheumatoid Arthritis Patients: Analyses using
Phase 3 Clinical Trials of Upadacitinib
2547 Upadacitinib Monotherapy Improves Patientreported
Outcomes in Patients with Rheumatoid
Arthritis and Inadequate Response to Methotrexate
2551 Rheumatoid Arthritis Treatment with Filgotinib:
Week 132 Safety Data from a Phase 2b Openlabel
Extension Study
Spondyloarthritis including Psoriatic Arthritis
– Clinical Poster III: Treatment
2565 Safety and Efficacy of Tofacitinib, an Oral Janus
Kinase Inhibitor, up to 36 Months in Patients with
Active Psoriatic Arthritis: Data from the Third
Interim Analysis of OPAL Balance, an Open-label,
Long-term Extension Study
2588 Baseline Pain Severity as a Predictor of
Pain Improvement Following Treatment with
Tofacitinib in Psoriatic Arthritis
2594 Median Time to Pain Improvement in Patients
with Psoriatic Arthritis Treated with Tofacitinib
Systemic Lupus Erythematosus – Animal
Models Poster
2097 Monotherapy with Filgotinib, a JAK1-selective
Inhibitor, Reduces Disease Severity and Alters
Immune Cell Subsets in the NZB/W F1 Murine
Model of Lupus
ACR CONCURRENT ABSTRACT SESSION:
2:30 – 4:00PM
5T088 ACR Abstract: RA–DX, Manifestations,
& Outcomes IV: CV Co-morbidities
2815 Cardiovascular Safety – Update from up
to 6 Years of Treatment with Baricitinib in
Rheumatoid Arthritis Clinical Trials
2817 Cardiovascular Disease Risk with Biologics and
Tofacitinib Compared to Conventional Synthetic
DMARDs in Patients with Rheumatoid Arthritis
ACR CONCURRENT ABSTRACT SESSION:
4:30 – 6:00PM
5T106 ACR Abstract: Measures of Healthcare
Quality I: QI in RA
2858 Gaps in Patient Safety Performance before
Treatment with Biologic Disease-modifying
Antirheumatic Drugs or Tofacitinib in a Large
Academic Healthcare System
Wednesday, 24 October 2018
ACR CONCURRENT ABSTRACT SESSION:
9:00 – 10:30AM
6W009 ACR Abstract: RA–Etiology &
Pathogenesis II
2899 Sustained Drug-free Remission in Early RA
Following Methotrexate-based Strategy: Role of
the JAK-STAT Pathway
Chairman’s picks

Notes
Chairman’s picks

Notes
Chairman’s picks

Chairman’s picks

Register for all this FREE content at
www.cytokinesignalling.com
www.cytokinesignalling.com
info@cytokinesignalling.com
@CytokineForum
lnkd.in/PyqQPm
Supported by an unrestricted educational grant from Pfizer Italia S.R.L. and Lilly.
Developed under the auspices of the
University of Glasgow